Quick Answer
Cogent Biosciences, Inc. reported Stockholders Equity of $636.37 million for the year ending 2025.
- Cogent Biosciences, Inc. showed an increase of +148.3% in Stockholders Equity from 2024 to 2025.
- This data is from Cogent Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$61.27 million | Q2 2018: $76.68 million | Q3 2018: $67.53 million | Q1 2019: $49.29 million | Q2 2019: $39.76 million | Q3 2019: $28.62 million | Q1 2020: $25.70 million | Q2 2020: $19.24 million | Q3 2020: -$22.17 million | Q1 2021: $226.76 million | Q2 2021: $212.80 million | Q3 2021: $197.24 million | Q1 2022: $187.86 million | Q2 2022: $319.39 million | Q3 2022: $289.94 million | Q1 2023: $223.56 million | Q2 2023: $348.43 million | Q3 2023: $302.90 million | Q1 2024: $422.33 million | Q2 2024: $373.22 million | Q3 2024: $314.66 million | Q1 2025: $219.00 million | Q2 2025: $155.04 million | Q3 2025: $302.46 million.
- Over the full 10 years of available data (2016 to 2025), Cogent Biosciences, Inc.'s Stockholders Equity has grown by 2,676.6%.
- Historical annual values: Fiscal year 2025: $636.37 million | Fiscal year 2024: $256.29 million | Fiscal year 2023: $257.80 million | Fiscal year 2022: $255.74 million | Fiscal year 2021: $214.18 million | Fiscal year 2020: $234.67 million | Fiscal year 2019: $31.76 million | Fiscal year 2018: $60.23 million | Fiscal year 2017: -$48.85 million | Fiscal year 2016: -$24.70 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: